clinical trial · NCT00631475
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
Actelion·phase3·completed·n = 128
Idiopathic Pulmonary FibrosisBosentan
brief summary
This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 (NCT00391443) will asses the long term safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis (IPF).
started
Apr 1, 2008
primary completion
Apr 1, 2010
completion
May 1, 2010
last updated
Feb 4, 2025
official title
Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol